<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03277066</url>
  </required_header>
  <id_info>
    <org_study_id>HP-5000-US-05</org_study_id>
    <nct_id>NCT03277066</nct_id>
  </id_info>
  <brief_title>A 4-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Knee Osteoarthritis</brief_title>
  <acronym>HP-5000</acronym>
  <official_title>A 4-week, Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2 Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Noven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Noven Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A 4-week, Randomized, Double-blind, Multicenter, Placebo-controlled Phase 2 Study to Evaluate
      the Efficacy and Safety of HP-5000 in Subjects with Osteoarthritis (OA) of the Knee
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized, double-blind, and placebo-controlled phase 2 study
      evaluating 2 formulations of HP-5000 in subjects with OA of the knee. The study will consist
      of up to 28-day Screening Phase that will include a Washout Period of current prescription
      and over the counter (OTC) analgesics, a 4-week double-blind Treatment Phase, and a 1-week
      safety Follow-up Period.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate Efficacy &amp; Safety of HP-5000 Topical Patches in Subjects With Osteoarthritis of the Knee: Change in Osteoarthritis pain score</measure>
    <time_frame>4 weeks</time_frame>
    <description>Primary efficacy endpoint is the change in Osteoarthritis of the Knee pain score between Baseline and Week 4.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Active Topical Patch 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac sodium 1 topical patches will be compared against placebo patches.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diclofenac Sodium Active Topical Patch 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Diclofenac sodium 2 topical patches will be compared against placebo patches.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Active Topical Patch 1</intervention_name>
    <description>HP-5000 Active Topical Patch 1 will be evaluated against placebo topical patches.</description>
    <arm_group_label>Diclofenac Sodium Active Topical Patch 1</arm_group_label>
    <other_name>NSAID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diclofenac Sodium Active Topical Patch 2</intervention_name>
    <description>HP-5000 Active Topical Patch 2 will be evaluated against placebo topical patches.</description>
    <arm_group_label>Diclofenac Sodium Active Topical Patch 2</arm_group_label>
    <other_name>NSAID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>The study will evaluate active topical patches against topical placebo patches.</description>
    <arm_group_label>Diclofenac Sodium Active Topical Patch 1</arm_group_label>
    <arm_group_label>Diclofenac Sodium Active Topical Patch 2</arm_group_label>
    <other_name>Placebo treatment</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 40 to 85 years with a clinical diagnosis of OA of the target knee
             according to the American College of Rheumatology (ACR) criteria, including:

          -  Symptoms for at least 6 months prior to screening, AND

          -  Knee pain in the target knee for 30 days of the preceding month (periarticular knee
             pain due to OA and not due to other conditions such as bursitis, tendonitis, etc.) AND

          -  The pain in the target knee required the use of nonsteroidal anti-inflammatory drugs
             (NSAIDs) either over the counter (OTC) per recommendation of a physician or
             prescribed.

        Exclusion Criteria:

          -  Body mass index (BMI) &gt; 40

          -  Any subject who disobeyed the restriction of prohibited therapies (i.e., use rescue
             medication) during Screening Washout Period.

          -  Secondary OA of the knee (rheumatoid arthritis, gout, psoriasis, syphilitic
             neuropathy, ochronosis, metabolic or other primary bone disease or acute trauma).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yamina Merazga, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Noven Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>HP-5000 Project Team</last_name>
    <phone>(551) 233-2652</phone>
    <email>HP5000@noven.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Noven Pharmaceuticals, Inc.</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>07310</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2017</study_first_submitted>
  <study_first_submitted_qc>September 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 8, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diclofenac</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

